Ratings JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

End-of-day quote Korea S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
30,550 ^KRW	-0.81%		-0.81%	-14.06%

03-14	JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-22	CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10 for the current year.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JW PHARMACEUTICAL CORPORATION	-14.06%	520M	-
ELI LILLY AND COMPANY	+30.38%	684B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	329B	B-
ABBVIE INC.	+3.73%	284B	C+
ASTRAZENECA PLC	+16.70%	240B	B+
NOVARTIS AG	+8.78%	208B	B-
ROCHE HOLDING AG	-7.93%	200B	A+
AMGEN INC.	+7.68%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes